MBody AI Overview
Valuation check: MBAI's ROE is -731.71%, below the Healthcare sector average of -100.59%.
Get informed when a big investor buys or sells
+ Follow-731.71%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
MBody AI (MBAI) currently reports a ROE of -731.71%. That is below the Healthcare sector average of -100.59%. Use the charts on this page to explore MBody AI's ROE history and peer comparisons.
MBody AI's ROE of -731.71% is lower than the Healthcare sector average of -100.59%. That is roughly 627.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but MBody AI's current -731.71% should be judged against Healthcare norms (sector average: -100.59%) and against MBAI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -731.71%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for MBody AI, and consider following MBAI for alerts when major investors trade the stock.
MBody AI is classified in the Healthcare sector. On ROE, it currently shows -731.71% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MBAI with unrelated industries.
